FDA Looks East—Here’s What Industry Needs to Know

Key Takeaways

• FDA seeks $2.5 M to staff Hanoi and Tokyo offices
• Vietnam imports rose tenfold, now 60% medical devices
• Tokyo office strengthens U.S.–Japan regulatory partnership
• Staffing and visa clearances could delay office openings

Pulse Analysis

The FDA’s renewed push to expand its foreign footprint reflects a strategic shift from past consolidation to proactive global engagement. In the FY2027 budget request, the agency earmarks $2.5 million and five full‑time equivalents to establish permanent offices in Hanoi and Tokyo. Lawmakers have explicitly called for these outposts to conduct unannounced inspections of food, drug, device, and aquaculture products, signaling heightened congressional focus on supply‑chain integrity for imports originating in East Asia.

Vietnam has emerged as a major source of FDA‑regulated goods, with import lines climbing from roughly 96,000 in FY2015 to over 961,000 in FY2025—a tenfold increase. The product mix has shifted dramatically; today, about 60% of Vietnamese imports are medical devices, underscoring the country’s growing role in the U.S. health‑care ecosystem. A Hanoi office would give inspectors direct, on‑site access, shortening response times and improving risk‑based oversight. Meanwhile, Tokyo offers a strategic gateway to the broader Asian market and deepens the burgeoning U.S.–Japan regulatory partnership, mirroring the PMDA’s recent Washington, D.C. presence.

For manufacturers and importers, the message is clear: preparation is essential. Companies with supply chains in Vietnam or Japan should audit inspection readiness, reinforce quality agreements with contract manufacturers, and anticipate more frequent, potentially unannounced, FDA visits. However, the agency’s history of staffing shortages and lengthy visa clearances suggests that full operational capacity may not materialize immediately. Firms that proactively engage with FDA’s training resources and align internal compliance programs with the agency’s evolving expectations will be best positioned to navigate the upcoming regulatory landscape.